Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 3,229 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Solution Clear all
Recruiting Phase 2 Interventional

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

NCT05705024
View directory record Official record
Conditions
Corneal Ulcer
Interventions
Mesenchymal Stromal Cells, Control Solution
Biological · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma

NCT01122680
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
5
States / cities
Denver, Colorado • Columbia, Missouri • Warrensburg, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 23, 2026, 9:03 AM EDT
Terminated Phase 4 Interventional

Plasma Resuscitation Without Lung Injury

NCT04681638
View directory record Official record
Conditions
Burns
Interventions
Pathogen-Reduced Plasma, Crystalloid Solutions
Drug
Lead sponsor
Coalition for National Trauma Research
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Birmingham, Alabama • Baltimore, Maryland • Nashville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma

NCT00753168
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
OT-730 ophthalmic solution, timolol maleate ophthalmic solution, OT-730 placebo
Drug
Lead sponsor
Othera Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Artesia, California • Roswell, Georgia • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2009 · Synced Oct 23, 2026, 9:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

Denosumab for Type 1 Diabetes

NCT06524960
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Denosumab, Placebo
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • Duarte, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 9:03 AM EDT
Recruiting Phase 2 Interventional

Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus

NCT07527650
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, T2DM
Interventions
HM15275, Placebo of HM15275
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
20
States / cities
Mesa, Arizona • Santa Clarita, California • DeLand, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Thoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic Surgery

NCT04117074
View directory record Official record
Conditions
Surgery, Analgesia
Interventions
Liposomal bupivacaine, Thoracic epidural analgesia (bupivacaine)
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease

NCT04365218
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
MEDI8367, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 23, 2026, 9:03 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Long-acting Local Vaginal Cuff Anesthesia Following Hysterectomy

NCT07842159
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Combined Bupivacaine and Exparel, Normal Saline (NS)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Tear Osmolarity Changes After Instilling Isotonic Hyaluronate Artificial Tears

NCT01614847
View directory record Official record
Conditions
Dry Eye
Interventions
Artificial tears
Drug
Lead sponsor
Thomas O Salmon, OD, PhD
Other
Eligibility
18 Years to 35 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tahlequah, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 23, 2026, 9:03 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Measurement of Insulin Levels in the Cerebrospinal Fluid of Healthy Adults After a Single Intranasal Dose - Middle Age

NCT06434038
View directory record Official record
Conditions
Healthy
Interventions
Low Dose Regular insulin, High Dose Regular insulin, 0.9% Saline
Drug · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
36 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 23, 2026, 9:03 AM EDT
Recruiting Not applicable Interventional

KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure

NCT05879835
View directory record Official record
Conditions
Pediatric Intestinal Failure
Interventions
KiteLock 4% Sterile Catheter Lock Solution, Heparin Lock Solution
Device
Lead sponsor
SterileCare Inc.
Industry
Eligibility
4 Weeks to 18 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Boston, Massachusetts • Omaha, Nebraska • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults

NCT02810340
View directory record Official record
Conditions
Meningococcal Vaccines
Interventions
Adjuvanted MCV-5, Non-Adjuvanted MCV-5, Menactra®
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain

NCT07053774
View directory record Official record
Conditions
Pain, Acute
Interventions
Intravenous oxytocin, Intravenous placebo, Intranasal oxytocin, Intranasal placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

Convergence Insufficiency Treatment Study (CITS)

NCT01515943
View directory record Official record
Conditions
Convergence Insufficiency
Interventions
Active home-based computer vergence/accommodative therapy, Near target push-ups, Placebo home-based computer vergence/accommodative therapy, Placebo yoked prism flippers
Other · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
9 Years to 17 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Cranberry TWP, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 23, 2026, 9:03 AM EDT
Recruiting Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis

NCT06429176
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
SPL84, Placebo
Drug · Other
Lead sponsor
SpliSense Ltd.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Denver, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 23, 2026, 9:03 AM EDT
Withdrawn Phase 2 Interventional

Botulinum Toxin Type A for Neuroma Pain

NCT01374191
View directory record Official record
Conditions
Neuroma
Interventions
onabotulinum toxin type-A, placebo, 2nd phase - onabotulinum toxin type-A
Drug · Other
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm

NCT04766723
View directory record Official record
Conditions
Essential Tremor of the Upper Limb
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Tampa, Florida • Omaha, Nebraska • Las Vegas, Nevada + 6 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

NCT03663335
View directory record Official record
Conditions
Kidney Transplantation
Interventions
CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 23, 2026, 9:03 AM EDT
Withdrawn Phase 2 Interventional

Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms

NCT04734860
View directory record Official record
Conditions
Covid19
Interventions
COVI-AMG, Placebo
Biological · Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Garden Grove, California • Bradenton, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2022 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

NCT03392896
View directory record Official record
Conditions
Primary Hyperoxaluria
Interventions
DCR-PHXC, Placebo
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
6 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 2Phase 3 Interventional Results available

An Exploratory Study of PQ Grass 27600 SU

NCT04687059
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
PQ Grass, Active Placebo, Standard Placebo
Biological · Drug
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Lexington, Kentucky • White Marsh, Maryland • Ocean Township, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Early Ultrasound-guided Nerve Block for Painful Hand Injuries in the Emergency Department

NCT03195413
View directory record Official record
Conditions
Hand Injuries, Hand Injuries and Disorders
Interventions
Ultrasound-guided forearm nerve block, 1:1 volume measured solution of: 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine, Bedside ultrasound machine
Procedure · Drug · Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study Comparing Calcium Acetate Oral Solution Versus Calcium Acetate Gelcaps in Healthy Volunteers

NCT00742820
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Calcium Acetate Oral Solution 667 mg per 5 mL, Calcium Acetate 667 mg GelCaps, Calcium Citrate 950 mg Caplets
Drug · Dietary Supplement
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Oct 23, 2026, 9:03 AM EDT